{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000431","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.173536+00:00","generated_at":"2026-06-28T19:59:21.126970+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Regen Biopharma engages Biotech Research Group for NR2F6 IP assessment at $25k total","bullets":["Engaged BRG to perform a GAP assessment of CRO work on NR2F6 checkpoint pre-clinical protocols, raw data, and completion report.","Total fee of $25,000 due immediately upon SOW signing; work to be completed by November 15, 2021.","Deliverables include a gap assessment report and a regulatory strategy work package for NR2F6 IP.","Scope of Work Order effective October 11, 2021, under existing Master Services Agreement dated May 12, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000431","json":"https://secwatch.observer/filing/0001607062-21-000431.json","markdown":"https://secwatch.observer/filing/0001607062-21-000431.md","text":"https://secwatch.observer/filing/0001607062-21-000431.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000431/0001607062-21-000431-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000431/rgbp101821form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T19:59:21.126970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}